Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Free-Cash-Flow-To-Equity" stands at 28.13 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Johnson & Johnson's third quarter result of 3.24 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 3,013.46 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 3.24 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 551.60 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 28.13 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 16.36 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 17.68 Billion United States Dollars compared to the value the year prior.
The 1 year change is 17.68 Billion United States Dollars.
The 3 year change is 9.25 Billion United States Dollars.
The 5 year change is 1.86 Billion United States Dollars.
The 10 year change is 8.30 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Free Cash Flow To Equity | 905,699,262,464.00 |
![]() | AbbVie Inc - Free Cash Flow To Equity | 399,570,305,024.00 |
![]() | Roche Holding AG - Free Cash Flow To Equity | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Free Cash Flow To Equity | 280,205,508,085.11 |
![]() | Novartis AG - Free Cash Flow To Equity | 255,096,620,580.91 |